Meeting
2011 ASCO Annual Meeting
Evaluation of p53 mutation as a predictive biomarker for outcome to chemotherapy in ovarian cancer.
Authors
A. H. Calvert
University College London, London, United Kingdom
A. H. Calvert , J. C. Jackson , C. Hutton , A. M. Swart , W. Qian , C. Kwakye , R. Fossati , A. Lissoni , P. G. Harper , N. Colombo , R. J. Edmondson , J. Lunec
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Prognostic Factors
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10522)
Abstract #
10522
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2022 ASCO Annual Meeting
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
First Author: Florian Heitz
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.
First Author: Daniel M. Geynisman
Poster
2020 ASCO Virtual Scientific Program
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.
First Author: Mario Javier Pineda